A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Clinical trial NCT07213804 · RECRUITING

Trial details

NCT number: NCT07213804
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Ovarian Neoplasms Fallopian Tube Neoplasms Peritoneal Neoplasms Neoplasm Metastasis

Start date: 2025-10-22
Primary completion: 2028-11-01
Enrollment: 1630

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.